Industry News

Boehringer Ingelheim today announced it has completed enrollment for the pivotal Phase III trial of BI695501, a biosimilar candidate to adalimumab (AbbVie’s Humira®). This announcement was made following recent results from a Phase I trial that demonstrated pharmacokinetic bioequivalence with both the U.S.-licensed and EU-approved reference products.These Phase I data for BI695501 were discussed at the American College of Rheumatology / Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in San Francisco.

UBM India is all set to host the 3rd Annual India Pharma Awards scheduled on 30th November, 2015 at ITC Maratha, Mumbai and pleased to announce TAKE Solutions as our presenting partner. The event is more than an ‘Award Night’ and it will bring together the luminaries of the Pharmaceutical Industry combined with a night of glamour, entertainment, jubilation and the pride of being the crème de la crème of the Indian Pharmaceutical sector.

India aims to scale up start-ups in the biotechnology sector to at least 1,500 in the next two to three years to boost technological interventions in the health and agriculture sectors, a senior biotechnology department official said.

WuXi PharmaTech (Cayman) Incand Eli Lilly and Company announced that they have entered into a strategic collaboration to develop, manufacture and commercialize a novel small molecule in China.

The U.S. Food and Drug Administration approved Cotellic (cobimetinib) to be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can’t be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation).

[adsense:336x280:8701650588]

DS Biopharma, a biopharmaceutical company, announced that its patent covering the use of bioactive active pharmaceutical ingredient (API) DS102 (15-HEPE) for fatty liver disorders has been granted by the European Patent Office (EPO).

Five years after the introduction of MenAfriVac, an affordable vaccine for meningitis A produced by Indian firm Serum Institute of India, immunization has led to the near elimination of the deadly disease in Africa's 'meningitis belt', says the Clinical Infectious Diseases journal.

Abcam, a supplier of life science research tools, is to acquire AxioMx, an American antibody technology firm, for US$25m. The firm, based in Cambridge, UK has agreed the deal and will pay $20m to AxioMx with further performance payments of up to $5m over five years. The deal is expected to be completed by the end of this month.

Roche announced the launch of the VENTANA HE 600 system, the latest fully automated hematoxylin and eosin (H&E) tissue staining system that enhances patient and technician safety and produces exceptional staining quality.
The VENTANA HE 600 system delivers fresh reagents on each individual slide without relying on user-supplied alcohol and deionized (DI) water, resulting in improved consistency and quality in tissue staining. This individual slide staining technology mitigates the risk of specimen cross contamination that can occur with other technologies, helping to reduce patient misdiagnosis.

AstraZeneca, along with its global biologics research and development arm, MedImmune, will present positive data today from the Phase II trial of anifrolumab for the treatment of moderate-to-severe systemic lupus erythematosus (SLE or lupus) at the American College of Rheumatology (ACR) 2015 Annual Scientific Meeting in San Francisco.